BMJ: Quality Assessment of Clinical Guidelines for Early New Coronary Pneumonia

Researchers recently assessed the feasibility of early clinical guidelines for 2019 coronavirus disease (covid-19)researchers collected relevant information as of March 14, 2020, including clinical management guidelines related to covid-19, MERS and Severe Acute Respiratory Syndrome (SARS) developed by international and national scientific organizations, governments and non-governmental organizations, using the Research and Assessment Guidelines Assessment Tool (AGREE) II to assess the quality of the guidelinesCompare differences in the quality and content of early covid-19 guidelines with MERS and SARS clinical guidelinesstudy included 42 guidelines, 18 of which were specific to covid-19In general, clinical guidelines lack detail and cover a narrow range of topicsFor example, the recommendations of different guidelines vary with regard to the use of antiviral drugsOverall quality is poor, especially in terms of stakeholder engagement, applicability and editorial independenceThe link between the evidence and the recommendations is limitedLittle information is available on vulnerable groups such as pregnant women, children and the elderlystudy found that the clinical guidelines provided in the early stages of the covid-19 pandemic were methodologically flawed and ignored vulnerable groups such as the elderlyIn the context of public health emergencies, clinical guidelines are more needed to be developed in line with frameworks, methodological sciences, and to include vulnerable populations